Business

Biotech, pharma, and money in science

Triple-negative breast cancer
Biotech

After 37 years of trying, this biotech nears a first drug approval in breast cancer

By Adam Feuerstein

WALGREENS
Business

Microsoft and Walgreens pair up amid fierce competition to deliver digital health care

By Casey Ross

Larry Merlo
Business

CVS CEO: Anything Amazon does, we will do better — including, maybe, delivery by drone

By Ike Swetlitz

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: ‘Netflix’ model for hep C drugs proceeds; J&J hikes drug prices

By Elizabeth Cooney

Len Schleifer
Pharma

Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

By Ed Silverman and Matthew Herper

JPM 2019 - Painted Ladies
Go West

Where’s Big Tech at biopharma’s big bash?

By Rebecca Robbins

Pharmalot

Pharmalittle: Allergan CEO says ‘social contract’ intact; medical marketing skyrockets to $30 billion

By Elizabeth Cooney

Ginni Rometty CES
Exclusive

IBM isn’t retreating from using Watson in health care, CEO Rometty says

By Casey Ross

Pharmalot

Pharmalittle: Existing drugs driving higher prices; Baselga lands at AstraZeneca

By Elizabeth Cooney

Pharmalot

Pharmalittle: Lilly makes a huge bet on Loxo; what about the Michaels?

By Elizabeth Cooney and Ed Silverman

Postpartum depression
Biotech

Sage Therapeutics pill improves postpartum depression in pivotal clinical trial

By Adam Feuerstein

Mike Huckman headshot
Biotech

What not to say at J.P. Morgan, according to a conference veteran

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

JPM 2019 - Painted Ladies
Biotech

The pull of JPM may be irresistible, but will San Francisco’s problems push people away?

By Adam Feuerstein, Rebecca Robbins, and Damian Garde

Biotech

9 big takeaways from the $74 billion Bristol-Celgene deal

By Damian Garde, Adam Feuerstein, and Ed Silverman

Bristol-Myers Squibb
Business

Why Bristol-Myers Squibb’s Giovanni Caforio is buying Celgene, in his own words

By Matthew Herper

Pharmalot

Pharmalittle: Bristol-Myers to pay $74 billion for Celgene; Trump expects drug prices to fall

By Ed Silverman

Celgene
Biotech

Bristol-Myers Squibb will acquire Celgene in blockbuster $74B deal

By Adam Feuerstein and Matthew Herper

Bobby Coughlin
Biotech

For head of Massachusetts biotech trade group, drug progress is personal

By Jonathan Saltzman — Boston Globe

3 to Watch: Legislative Battles
Politics

3 state legislative battles to watch in 2019

By Lev Facher

3 to Watch: Biotech
Biotech

3 trends in biotech to watch in 2019

By Damian Garde

Biotech

After Sarepta, going after the genetic causes of epilepsies at Stoke

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

Relay Therapeutics raises $400 million in venture capital funding

By Jonathan Saltzman — Boston Globe

Peanuts
Biotech

DBV Technologies pulls peanut allergy treatment from FDA review

By Adam Feuerstein

Business

Judge dismisses lawsuit accusing Craig Venter of stealing trade secrets

By Rebecca Robbins

China Glaxo Investigation
Business

Drug makers GSK, Pfizer will merge health care divisions

By Associated Press

Budtender
Pharma

Novartis unit teams up with medical marijuana producer, marking milestone for pharma

By Elizabeth Cooney

DNA Test
Health

What’s a polygenic risk score and how good is it at predicting disease?

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

Voice Mental Illness
Business

Tech companies enter the business of campus mental health care

By Deirdre Fernandes — Boston Globe

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy